The GlycoMark test vs HbA1c is an important comparison for anyone seeking a fuller understanding of blood glucose monitoring in diabetes care. HbA1c is the cornerstone of NHS diabetes management, reflecting average glucose control over two to three months. The GlycoMark test, which measures serum 1,5-anhydroglucitol (1,5-AG), offers a shorter window of approximately one to two weeks and is particularly sensitive to postprandial glucose spikes. While HbA1c is embedded in NICE guidance and routinely available on the NHS, the GlycoMark test is not currently recommended within UK clinical pathways. Understanding how these tests differ can help patients have more informed conversations with their diabetes care team.

What Are the GlycoMark Test and HbA1c?

HbA1c measures average blood glucose over 2–3 months via glycated haemoglobin, while the GlycoMark test measures serum 1,5-AG to detect recent hyperglycaemic episodes; only HbA1c is routinely used within NHS practice.

Monitoring blood glucose control is central to managing diabetes effectively. Two laboratory tests used in this context are the GlycoMark test and the HbA1c (glycated haemoglobin) test. While HbA1c is well established within NHS clinical practice and widely recognised by patients, the GlycoMark test is a less commonly used marker that offers a different perspective on glycaemic control.

The HbA1c test measures the proportion of haemoglobin in red blood cells that has become glycated — that is, chemically bonded to glucose. Because red blood cells have a lifespan of approximately 120 days, HbA1c reflects average blood glucose levels over the preceding two to three months. In the UK, results are expressed in millimoles per mole (mmol/mol) in line with IFCC standardisation, though percentage values are sometimes also quoted for reference.

The GlycoMark test, by contrast, measures serum levels of 1,5-anhydroglucitol (1,5-AG), a naturally occurring glucose-like compound obtained through food. Under normal circumstances, 1,5-AG is freely filtered by the kidneys and almost entirely reabsorbed. However, when blood glucose rises above the renal glucose threshold — typically in the region of 10 mmol/L, though this varies between individuals and with age and renal status — glucose competitively inhibits this reabsorption, causing 1,5-AG levels in the blood to fall. Lower serum 1,5-AG therefore indicates recent episodes of hyperglycaemia. This test is more widely used in the United States and parts of Asia. It is not included in NICE guidance and is not routinely available through NHS laboratories.

How Each Test Measures Blood Glucose Control

HbA1c accumulates through irreversible glycation of haemoglobin over red blood cell lifespan, whereas the GlycoMark test detects falls in serum 1,5-AG caused by competitive inhibition of renal reabsorption when glucose exceeds the renal threshold.

Understanding the underlying mechanisms of each test helps clarify what clinical information they provide and why they may complement one another in certain situations.

HbA1c works on the principle of non-enzymatic glycation. As blood glucose rises, glucose molecules bind irreversibly to haemoglobin within red blood cells. The higher and more sustained the blood glucose, the greater the proportion of glycated haemoglobin. Because this process accumulates over the lifespan of a red blood cell, HbA1c provides a retrospective average — it does not capture day-to-day fluctuations or short-term spikes in glucose.

The GlycoMark test operates through a different physiological mechanism. 1,5-AG is ingested daily through food and maintains a relatively stable serum concentration in individuals with normal glucose metabolism. When postprandial or fasting glucose levels exceed the renal threshold, urinary glucose excretion increases, and 1,5-AG reabsorption in the renal tubules is competitively inhibited by glucose. This leads to a measurable drop in serum 1,5-AG — changes may begin within days of sustained glycosuria, with the full effect typically apparent within one to two weeks. Conversely, when glucose control improves, 1,5-AG levels recover over a similar timeframe.

This means the GlycoMark test is particularly sensitive to postprandial glucose excursions and short-term changes in glycaemic control, offering a window of approximately one to two weeks rather than the two to three months reflected by HbA1c. Together, these two tests can theoretically provide both a short-term and longer-term picture of glucose management.

Key Differences Between GlycoMark and HbA1c

HbA1c reflects a 2–3 month glucose average and is internationally standardised and NHS-available, while GlycoMark reflects a 1–2 week window, lacks global standardisation, and is not commissioned by the NHS.

Although both tests relate to blood glucose control, they differ substantially in their timeframes, clinical applications, and availability within the UK healthcare system.

Timeframe of measurement:

• HbA1c reflects average glucose over 2–3 months

• GlycoMark (1,5-AG) reflects glucose excursions over approximately 1–2 weeks

Sensitivity to postprandial spikes: HbA1c may remain within an acceptable range even when a patient experiences frequent postprandial hyperglycaemic spikes, because these episodes may be offset by periods of lower glucose. The GlycoMark test is more sensitive to these excursions, potentially identifying patients whose overall average appears controlled but who are experiencing clinically significant glucose peaks after meals.

Standardisation and availability: HbA1c is internationally standardised (IFCC), widely available across NHS laboratories, and forms the cornerstone of NICE-recommended diabetes monitoring (NICE NG17 for type 1 diabetes in adults; NICE NG28 for type 2 diabetes in adults). The 1,5-AG assay used in the GlycoMark test does not have the same degree of global standardisation, and the test is not recommended within NICE guidance and is not routinely commissioned or provided by the NHS.

Conditions affecting reliability: Both tests can be influenced by specific clinical conditions, which is discussed further in a later section. Notably, HbA1c can be unreliable in haemoglobinopathies, whereas GlycoMark may be affected by renal impairment, dietary intake, and certain medicines.

Cost and accessibility: HbA1c testing is funded through NHS commissioning and is a routine part of diabetes care. GlycoMark testing, where available in the UK, is typically accessed through private laboratories and is not part of any standard NHS monitoring pathway.

When Clinicians in the UK May Use Each Test

HbA1c is the standard NHS monitoring tool per NICE NG17 and NG28; GlycoMark may be considered in specialist settings for patients with haemoglobinopathies or unreliable HbA1c, though fructosamine is more accessible in UK laboratories.

In routine NHS diabetes care, HbA1c remains the primary tool for monitoring long-term glycaemic control in both type 1 and type 2 diabetes. NICE guideline NG17 (type 1 diabetes in adults) and NICE guideline NG28 (type 2 diabetes in adults) recommend HbA1c measurement every three to six months depending on stability of control and treatment changes.

HbA1c is also used diagnostically in the UK: a result of 48 mmol/mol (6.5%) or above is consistent with a diagnosis of type 2 diabetes. In asymptomatic individuals, a confirmatory repeat test is required. However, HbA1c is not appropriate for diagnosis in several circumstances, including: suspected type 1 diabetes, children and young people, pregnancy, or in individuals with conditions that affect red blood cell turnover or haemoglobin structure (such as haemolytic anaemia or haemoglobinopathies). In these situations, plasma glucose measurements should be used instead.

The GlycoMark test does not currently feature in NICE or NHS guidance. However, there are clinical scenarios where a clinician — particularly in a specialist or research setting — might consider it:

• Patients with haemoglobinopathies (e.g., sickle cell disease, thalassaemia) where HbA1c results may be unreliable

• Patients with haemolytic anaemia or conditions causing shortened red blood cell survival, which artificially lower HbA1c

• Assessing postprandial control in patients whose HbA1c appears satisfactory but who report symptoms consistent with glucose spikes

• Short-term monitoring following a medication change or dietary intervention, where a two-to-three-month wait for HbA1c feedback is impractical

It is important to note that in the UK, fructosamine is sometimes considered when HbA1c is unreliable, as it reflects glucose control over approximately two to three weeks and is more readily available through NHS laboratories than 1,5-AG. However, NICE does not recommend fructosamine for routine monitoring; its use depends on local laboratory policy and clinical judgement. Patients should always discuss any additional testing with their GP or diabetes specialist team rather than seeking private tests independently.

Accuracy, Limitations, and Influencing Factors

HbA1c is unreliable in haemoglobinopathies, haemolytic anaemia, and pregnancy, while GlycoMark is uninterpretable in renal impairment or in patients taking SGLT2 inhibitors, which are now widely prescribed in UK practice.

No single biomarker provides a complete picture of glycaemic control, and both the GlycoMark test and HbA1c are subject to specific limitations that clinicians must consider when interpreting results.

Factors affecting HbA1c accuracy:

• Haemoglobinopathies (e.g., HbS, HbC, HbE variants) can interfere with certain assay methods, producing falsely high or low results; modern assay platforms have reduced but not eliminated this risk

• Haemolytic anaemia and conditions causing increased red blood cell turnover lower HbA1c independently of glucose levels

• Iron deficiency anaemia may falsely elevate HbA1c

• Pregnancy alters red blood cell dynamics and can affect HbA1c reliability, particularly in the second and third trimesters

• Chronic kidney disease and uraemia can interfere with some assay methods, though the degree of interference is assay-dependent

Factors affecting GlycoMark (1,5-AG) accuracy:

• Renal impairment significantly affects 1,5-AG reabsorption, making results increasingly unreliable as kidney function declines — results are generally considered uninterpretable in patients with an eGFR below approximately 60 mL/min/1.73 m²

• Dietary variation — as 1,5-AG is derived from food, very low carbohydrate or severely restricted diets may lower baseline levels independently of glucose control

• SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin, canagliflozin), which are now widely used in type 2 diabetes, heart failure, and chronic kidney disease management, lower the renal glucose threshold and cause glycosuria even at normal blood glucose levels — this directly suppresses 1,5-AG reabsorption and renders the GlycoMark test uninterpretable in patients taking these medicines

• Pregnancy is also associated with lower 1,5-AG levels due to altered renal handling

Given the widespread use of SGLT2 inhibitors in UK clinical practice, this represents a particularly significant limitation of the GlycoMark test in the current treatment landscape.

Current NHS and NICE Guidance on Diabetes Monitoring

NICE recommends HbA1c targets of 48 mmol/mol for type 1 and low-hypoglycaemia-risk type 2 diabetes, and supports CGM for eligible patients; the GlycoMark test is not recommended within any current NICE or NHS guidance.

Within the UK, diabetes monitoring is guided primarily by NICE, with HbA1c at the centre of both diagnostic and ongoing management pathways.

For type 2 diabetes, NICE guideline NG28 recommends an HbA1c target of 48 mmol/mol (6.5%) for individuals whose glucose-lowering treatment does not carry a risk of hypoglycaemia (for example, those managed by lifestyle measures or metformin alone). A target of 53 mmol/mol (7.0%) is recommended for those taking medicines associated with a risk of hypoglycaemia, such as insulin or sulfonylureas. For type 1 diabetes, NICE guideline NG17 recommends a target of 48 mmol/mol where achievable without problematic hypoglycaemia.

NICE also recommends the use of real-time continuous glucose monitoring (rtCGM) and intermittently scanned CGM (isCGM, e.g., Libre systems) for eligible patients. Current NICE guidance supports offering rtCGM or isCGM to all adults with type 1 diabetes, and to selected groups with type 2 diabetes (including those on insulin with specific clinical needs) and during pregnancy with diabetes. These technologies provide real-time glucose data and time-in-range metrics, offering a more granular view of glycaemic variability than HbA1c alone — and in some respects addressing the same clinical gap that the GlycoMark test aims to fill.

The GlycoMark test is not recommended within NICE guidance and is not routinely commissioned or provided by the NHS. Patients should be aware that accessing it privately does not replace the value of HbA1c or CGM within a structured diabetes care plan.

When to contact your GP or diabetes team:

• If your HbA1c is consistently above your agreed target

• If you experience symptoms of hyperglycaemia (excessive thirst, frequent urination, fatigue) despite apparently controlled HbA1c

• If you are considering private testing and wish to discuss whether it is appropriate for your circumstances

• If you have a condition such as a haemoglobinopathy that may affect HbA1c reliability

Seek urgent medical attention (call 999 or go to your nearest A&E) if you develop symptoms that may suggest diabetic ketoacidosis (DKA) or hyperosmolar hyperglycaemic state (HHS), including vomiting, severe abdominal pain, deep or laboured breathing, confusion, or signs of severe dehydration. These are medical emergencies.

Not sure if this is normal? Chat with one of our pharmacists →

Regular review with your diabetes care team remains the most effective approach to monitoring and managing blood glucose safely within the NHS framework.

Frequently Asked Questions